| EMA number | EMEA/H/C/000609 |
| ATC code | V03AF08 |
| Authorisation | 25 October 2005 |
| Withdrawn | 1 April 2016 |
| Revision | 19 |
Kepivance is indicated to decrease the incidence, duration and severity of oral mucositis in adult patients with haematological malignancies receiving myeloablative radiochemotherapy associated with a high incidence of severe mucositis and requiring autologous-haematopoietic-stem-cell support.